IHH and leukocyte adhesion deficiency: To genetically test the requirement of IHH to suppress LAD tumorigenesis and growth, we used the pSECC lentiviral in vivo CRISPR/Cas9 system [53] that encodes for Cre recombinase to initiate tumorigenesis, Cas9 for gene editing, and sgRNA against the gene of interest.